On August 26, WUXI BIO rose 4.02% in regular trading, trading at HK$53.95/share, with turnover of HK$496 million. The stock extended gains following the release of robust interim results and an upward revision to full-year guidance.

On August 25, WUXI BIO reported H1 revenue of RMB 11.787 billion, up 18.4% year-over-year. Gross profit surged 28.1% to RMB 5.448 billion, with gross margin improving from 42.7% to 46.2%. Adjusted net profit attributable to shareholders reached RMB 3.306 billion, representing a 38.4% year-over-year increase. The company simultaneously raised its full-year performance guidance, citing unfulfilled orders of approximately US$5.5 billion over the next three years, up approximately 30% year-over-year, a record high. The company targets 300 IND submissions and 20 BLA/MAA filings annually by 2027. The broader CXO sector also rallied, with the industry entering a profit delivery phase supported by strong global biotech funding of US$267.5 billion in H1, up 58.5% year-over-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)